Forty years of human G-CSF: A short history in time

被引：2

作者：

Welte, Karl ^{[1
]}

机构：

[1] Univ Childrens Hosp, Tubingen, Germany

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 04期

关键词：

G-CSF; recombinant G-CSF; Filgrastim; Lenograstim; congenital neutropenia; chemotherapy induced neutropenia; COLONY-STIMULATING FACTOR; CELLS; NEUTROPENIA; PURIFICATION;

D O I：

10.1111/bjh.19713

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Human G-CSF was identified in 1984 at Memorial Sloan-Kettering Cancer Centre, New York. Based on these findings, recombinant G-CSF was developed by Amgen, Thousand Oaks. In 1987, clinical trials began using recombinant G-CSF in cancer patients following chemotherapy to reduce the duration of neutropenia and in patients with congenital neutropenia (CN) to increase the number of neutrophils. It has changed the quality of life for many cancer patients and saved the lives of many patients with (CN).

引用

页码：1296 / 1298

页数：3

共 50 条

[41] The kinetics of G-CSF folding
Brems, DN
PROTEIN SCIENCE, 2002, 11 (10) : 2504 - 2511
[42] Short-Term Costs Associated With Primary Prophylactic G-CSF Use During Chemotherapy
Rajan, Suja S.
Carpenter, William R.
Stearns, Sally C.
Lyman, Gary H.
AMERICAN JOURNAL OF MANAGED CARE, 2013, 19 (02) : 150 - 159
[43] Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis
Li, Xiang
Zheng, Huan
Yu, Man-Cheng
Wang, Wei
Wu, Xin-Hong
Yang, Dong-Mei
Xu, Juan
SUPPORTIVE CARE IN CANCER, 2020, 28 (11) : 5085 - 5097
[44] Managing myelotoxicities of breast cancer chemotherapies: what is the role for G-CSF?
Cameron, David
Aapro, Matti
EJC SUPPLEMENTS, 2008, 6 (02): : 17 - 23
[45] Stem Cell Mobilization with G-CSF versus Cyclophosphamide plus G-CSF in Mexican Children
Vazquez Meraz, Jose Eugenio
Arellano-Galindo, Jose
Martinez Avalos, Armando
Mendoza-Garcia, Emma
Jimenez-Hernandez, Elva
STEM CELLS INTERNATIONAL, 2016, 2016
[46] Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022
Yoshinami, Tetsuhiro
Nozawa, Kazuki
Yokoe, Takamichi
Ozaki, Yukinori
Nishio, Hiroshi
Tsuchihashi, Kenji
Ichihara, Eiki
Miura, Yuji
Endo, Makoto
Yano, Shingo
Maruyama, Dai
Susumu, Nobuyuki
Takekuma, Munetaka
Motohashi, Takashi
Ito, Mamoru
Baba, Eishi
Ochi, Nobuaki
Kubo, Toshio
Uchino, Keita
Kimura, Takahiro
Kamiyama, Yutaro
Nakao, Shinji
Tamura, Shinobu
Nishimoto, Hitomi
Kato, Yasuhisa
Sato, Atsushi
Takano, Toshimi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (06) : 681 - 688
[47] New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy
Theyab, Abdulrahman
Alsharif, Khalaf F.
Alzahrani, Khalid J.
Oyouni, Atif Abdulwahab A.
Hawsawi, Yousef MohammedRabaa
Algahtani, Mohammad
Alghamdi, Saad
Alshammary, Amal F.
FRONTIERS IN ONCOLOGY, 2023, 12
[48] Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies
Tonra, James R.
Lloyd, G. Kenneth
Mohanlal, Ramon
Huang, Lan
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (02) : 461 - 468
[49] Hypoplastic acute myeloid leukemia in an elderly patient. A long-term partial remission with low-dose prednisone and G-CSF
Islam, Anwarul
CLINICAL CASE REPORTS, 2019, 7 (07): : 1285 - 1290
[50] Efficient differentiation of human neutrophils with recapitulation of emergency granulopoiesis in human G-CSF knockin humanized mice
Ito, Ryoji
Katano, Ikumi
Kwok, Immanuel W. H.
Ng, Lai Guan
Ida-Tanaka, Miyuki
Ohno, Yusuke
Mu, Yunmei
Morita, Hanako
Nishinaka, Eiko
Nishime, Chiyoko
Mochizuki, Misa
Kawai, Kenji
Chien, Tay Hui
Zhao Yunqian
Fan Yiping
Hua, Liew Hui
Celhar, Teja
Chan, Jerry Kok Yen
Takahashi, Takeshi
Goto, Motohito
Ogura, Tomoyuki
Takahashi, Riichi
Ito, Mamoru
CELL REPORTS, 2022, 41 (12):

← 1 2 3 4 5 →